Mark Konijnenberg

8.5k total citations · 3 hit papers
139 papers, 5.4k citations indexed

About

Mark Konijnenberg is a scholar working on Radiology, Nuclear Medicine and Imaging, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Konijnenberg has authored 139 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Radiology, Nuclear Medicine and Imaging, 47 papers in Epidemiology and 42 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Konijnenberg's work include Radiopharmaceutical Chemistry and Applications (100 papers), Neuroendocrine Tumor Research Advances (47 papers) and Medical Imaging Techniques and Applications (45 papers). Mark Konijnenberg is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (100 papers), Neuroendocrine Tumor Research Advances (47 papers) and Medical Imaging Techniques and Applications (45 papers). Mark Konijnenberg collaborates with scholars based in Netherlands, Germany and Belgium. Mark Konijnenberg's co-authors include Eric P. Krenning, Marion de Jong, Erik de Blois, Dik J. Kwekkeboom, Katarina Sjögreen Gleisner, Wouter A.P. Breeman, Glenn Flux, P.P.M. Kooij, Ho Sze Chan and Claudio Chiesa and has published in prestigious journals such as PLoS ONE, Biomaterials and Scientific Reports.

In The Last Decade

Mark Konijnenberg

138 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative ¹⁷⁷Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy

2015 240 citations Mark Konijnenberg et al. Journal of Nuclear Medicine profile →
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

2022 138 citations Pablo Mínguez Gabiña, Mark Konijnenberg et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds

2022 114 citations Mark Konijnenberg, Ken Herrmann et al. European Journal of Nuclear Medicine and Molecular Imaging profile →

Peers

Countries citing papers authored by Mark Konijnenberg

Since Specialization

Citations

This map shows the geographic impact of Mark Konijnenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Konijnenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Konijnenberg more than expected).

Fields of papers citing papers by Mark Konijnenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Konijnenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Konijnenberg. The network helps show where Mark Konijnenberg may publish in the future.

Co-authorship network of co-authors of Mark Konijnenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Konijnenberg. A scholar is included among the top collaborators of Mark Konijnenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Konijnenberg. Mark Konijnenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose–response and threshold absorbed doses 2024 ·European Journal of Nuclear Medicine and Molecular Imaging ·Jean‐Pierre Pouget, Pablo Mínguez Gabiña, Ken Herrmann, Désirèe Deandreis, Mark Konijnenberg, David Taïeb, Fijs W. B. van Leeuwen, Jens Kurth, Uta Eberlein, Michael Laßmann, Katharina Lueckerath, (unknown)	4
2	Accuracy of holmium-166 SPECT/CT quantification over a large range of activities 2024 ·EJNMMI Physics ·(unknown), (unknown), (unknown), M. Bakker, Mark Konijnenberg, J. Frank W. Nijsen	1
3	New Radiolabeled Exendin Analogues Show Reduced Renal Retention 2023 ·Molecular Pharmaceutics ·Lieke Joosten, Cathelijne Frielink, (unknown), (unknown), Fritz Andreae, Mark Konijnenberg, Sandra Heskamp, Martin Gotthardt, Maarten Brom	4
4	Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry 2023 ·Nuclear Medicine Communications ·Maike J.M. Uijen, Bastiaan M. Privé, Carla M.L. van Herpen, Harm Westdorp, (unknown), (unknown), Martin Gotthardt, Mark Konijnenberg, Steffie M. B. Peters, James Nagarajah	17
5	[212Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors 2023 ·Pharmaceuticals ·(unknown), (unknown), (unknown), (unknown), (unknown), Debra Stuurman, Erik de Blois, (unknown), Karlijn van der Schilden, Marion de Jong, Mark Konijnenberg, Yann Seimbille	11
6	Urinary excretion kinetics of [177Lu]Lu-PSMA-617 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), (unknown), Antoi P.W. Meeuwis, Marcel J. R. Janssen, Mark Konijnenberg, James Nagarajah, Steffie M. B. Peters	2
7	Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment 2022 ·Clinical Cancer Research ·(unknown), Egbert Oosterwijk, Johan Bussink, Harm Westdorp, Mark Konijnenberg, Sandra Heskamp	40
8	Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours 2021 ·Nuclear Medicine and Biology ·(unknown), Julie Nonnekens, Mark Konijnenberg, Sarah Baatout, Marion de Jong, An Aerts	42
9	Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems 2020 ·EJNMMI Physics ·Steffie M. B. Peters, (unknown), Niels R. van der Werf, (unknown), Floris H. P. van Velden, Antoi P.W. Meeuwis, Mark Konijnenberg, Martin Gotthardt, Hugo W. A. M. de Jong, Marcel Segbers	39
10	EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy 2020 ·European Journal of Nuclear Medicine and Molecular Imaging ·Mark Konijnenberg, Ken Herrmann, Carsten Kobe, Frederik A. Verburg, Cécilia Hindorf, Roland Hustinx, Michael Laßmann	59
11	Prostate cancer imaging and therapy 2018 ·Lucia Zanoni, Cristina Nanni, Stefano Fanti, Martin Béhé, Wolfgang Römer, (unknown), David Gilmore, Giorgio Testanera, Giovanna Pepe, Y. Tsang, Michelle Leech, Sarah M. Schwarzenböck, Bernd J. Krause, Jens Kurth, Mark Konijnenberg, Domenico Albano, Rexhep Durmo, Laura Evangelista, Federico Caobelli	2
12	Pretargeted radionuclide therapy of HER2-expressing SKOV-3 human xenografts using an Affibody molecule-based PNA-mediated pretargeting 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Kristina Westerlund, Mark Konijnenberg, Bogdan Mitran, Maryam Oroujeni, Marion de Jong, Amelie Eriksson Karlström, Anna Orlova, Vladimir Tolmachev	1
13	In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies 2015 ·Theranostics ·Kristell L.S. Chatalic, Mark Konijnenberg, Julie Nonnekens, Erik de Blois, (unknown), (unknown), Luc Brunel, Jean‐Alain Fehrentz, Jean Martínez, Dik C. van Gent, Berthold A. Nock, Θεοδοσία Μάινα, Wytske M. van Weerden, Marion de Jong	53
14	Utilizing High-Energy γ-Photons for High-Resolution ²¹³Bi SPECT in Mice 2015 ·Journal of Nuclear Medicine ·(unknown), Ho Sze Chan, Marlies C Goorden, Alfred Morgenstern, Frank Bruchertseifer, Freek J. Beekman, Marion de Jong, Mark Konijnenberg	31
15	[ ¹¹¹ In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy 2014 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown), Boen L.R. Kam, Gerben A. Koning, Mark Konijnenberg, Timo L.M. ten Hagen, (unknown), Eric P. Krenning, Marion de Jong, Casper H.J. van Eijck	23
16	Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? 2011 ·European Journal of Nuclear Medicine and Molecular Imaging ·Stéphan Walrand, Glenn Flux, Mark Konijnenberg, Roelf Valkema, Eric P. Krenning, Renaud Lhommel, Stanislas Pauwels, François Jamar	53
17	Low-Dose-Rate Irradiation by ¹³¹ I Versus High-Dose-Rate External-Beam Irradiation in the Rat Pancreatic Tumor Cell Line CA20948 2004 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown), Astrid Capello, Bert F. Bernard, (unknown), Mark Konijnenberg, Wout A. P. Breeman, Eric P. Krenning, Marion de Jong	12
18	Is the Renal Dosimetry for [ ⁹⁰ Y-DOTA ⁰ , Tyr ³ ]Octreotide Accurate Enough to Predict Thresholds for Individual Patients? 2003 ·Cancer Biotherapy and Radiopharmaceuticals ·Mark Konijnenberg	27
19	PROCEEDINGS OF THE DUTCH SOCIETY FOR CLINICALPHARMACOLOGY AND BIOPHARMACY 2000 ·British Journal of Clinical Pharmacology ·Mark Konijnenberg, Gregory J. Ensing, (unknown), Rob Barto, (unknown), (unknown), (unknown), Julia Lohman, P. M. Hooymans	1
20	Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. 2000 ·PubMed ·Michael G. Stabin, Mark Konijnenberg	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact